|
1
|
Taylor EN, Stampfer MJ and Curhan GC:
Diabetes mellitus and the risk of nephrolithiasis. Kidney Int.
68:1230–1235. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Chang IH, Lee YT, Lee DM, Kim TH, Myung
SC, Kim YS and Ahn SH: Metabolic syndrome, urine pH, and
time-dependent risk of nephrolithiasis in Korean men without
hypertension and diabetes. Urology. 78:753–758. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Madore F, Stampfer MJ, Rimm EB and Curhan
GC: Nephrolithiasis and risk of hypertension. Am J Hypertens.
11:46–53. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Khan SR: Crystal-induced inflammation of
the kidneys: Results from human studies, animal models, and
tissue-culture studies. Clin Exp Nephrol. 8:75–88. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Lee YH, Huang WC, Tsai JY, Lu CM, Chen WC,
Lee MH, Hsu HS, Huang JK and Chang LS: Epidemiological studies on
the prevalence of upper urinary calculi in Taiwan. Urol Int.
68:172–177. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Rittling SR, Matsumoto HN, McKee MD, Nanci
A, An XR, Novick KE, Kowalski AJ, Noda M and Denhardt DT: Mice
lacking osteopontin show normal development and bone structure but
display altered osteoclast formation in vitro. J Bone Miner Res.
13:1101–1111. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Watts RW: Idiopathic urinary stone
disease: possible polygenic aetiological factors. QJM. 98:241–246.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Worcester EM and Beshensky AM: Osteopontin
inhibits nucleation of calcium oxalate crystals. Ann N Y Acad Sci.
760:375–377. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Tsuji H, Shimizu N, Nozawa M, Umekawa T,
Yoshimura K, De Velasco MA, Uemura H and Khan SR: Osteopontin
knockdown in the kidneys of hyperoxaluric rats leads to reduction
in renal calcium oxalate crystal deposition. Urolithiasis.
42:195–202. 2014.PubMed/NCBI
|
|
10
|
Giachelli CM, Lombardi D, Johnson RJ,
Murry CE and Almeida M: Evidence for a role of osteopontin in
macrophage infiltration in response to pathological stimuli in
vivo. Am J Pathol. 152:353–358. 1998.PubMed/NCBI
|
|
11
|
Umekawa T, Yamate T, Amasaki N, Kohri K
and Kurita T: Osteopontin mRNA in the kidney on an experimental rat
model of renal stone formation without renal failure. Urol Int.
55:6–10. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Konya E, Umekawa T, Iguchi M and Kurita T:
The role of osteopontin on calcium oxalate crystal formation. Eur
Urol. 43:564–571. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Chen WC, Lu HF, Chen HY, Hsu CD and Tsai
FJ: Arginine form of p21 gene codon 31 is less prominent in
patients with calcium oxalate stone. Urol Res. 29:94–97. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Giacopelli F, Marciano R, Pistorio A,
Catarsi P, Canini S, Karsenty G and Ravazzolo R: Polymorphisms in
the osteopontin promoter affect its transcriptional activity.
Physiol Genomics. 20:87–96. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Chiocchetti A, Indelicato M, Bensi T,
Mesturini R, Giordano M, Sametti S, Castelli L, Bottarel F,
Mazzarino MC, Garbarini L, et al: High levels of osteopontin
associated with polymorphisms in its gene are a risk factor for
development of autoimmunity/lymphoproliferation. Blood.
103:1376–1382. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Marciano R, D'Annunzio G, Minuto N,
Pasquali L, Santamaria A, Di Duca M, Ravazzolo R and Lorini R:
Association of alleles at polymorphic sites in the Osteopontin
encoding gene in young type 1 diabetic patients. Clin Immunol.
131:84–91. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Chiocchetti A, Comi C, Indelicato M,
Castelli L, Mesturini R, Bensi T, Mazzarino MC, Giordano M,
D'Alfonso S, Momigliano-Richiardi P, et al: Osteopontin gene
haplotypes correlate with multiple sclerosis development and
progression. J Neuroimmunol. 163:172–178. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
D'Alfonso S, Barizzone N, Giordano M,
Chiocchetti A, Magnani C, Castelli L, Indelicato M, Giacopelli F,
Marchini M, Scorza R, et al: Two single-nucleotide polymorphisms in
the 5′ and 3′ ends of the osteopontin gene contribute to
susceptibility to systemic lupus erythematosus. Arthritis Rheum.
52:539–547. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Juge PA, van Steenbergen HW, Constantin A,
Tobon GJ, Schaeverbeke T, Gazal S, Combe B, Devauchelle-Pensec V,
Nigon D, van der Helm-van Mil AH, et al: SPP1 rs9138 variant
contributes to the severity of radiological damage in
anti-citrullinated protein autoantibody-negative rheumatoid
arthritis. Ann Rheum Dis. 73:1840–1843. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Gazal S, Sacre K, Allanore Y, Teruel M,
Goodall AH, Tohma S, Alfredsson L, Okada Y, Xie G, Constantin A, et
al: The CARDIOGENICS consortium: Identification of secreted
phosphoprotein 1 gene as a new rheumatoid arthritis susceptibility
gene. Ann Rheum Dis. 74:e192015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Glas J, Seiderer J, Bayrle C, Wetzke M,
Fries C, Tillack C, Olszak T, Beigel F, Steib C, Friedrich M, et
al: The role of osteopontin (OPN/SPP1) haplotypes in the
susceptibility to Crohn's disease. PLoS One. 6:e293092011.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Safarinejad MR, Shafiei N and Safarinejad
S: Association between polymorphisms in osteopontin gene (SPP1) and
first episode calcium oxalate urolithiasis. Urolithiasis.
41:303–313. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Tugcu V, Simsek A, Tarhan T, Atalar F,
Bitkin A, Tasci AI, Kural AR and Altug T: OPN gene polymorphism
(Ala250) and lower serum OPN levels are associated with
urolithiasis. Ren Fail. 35:825–829. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Mo L, Huang HY, Zhu XH, Shapiro E, Hasty
DL and Wu XR: Tamm-Horsfall protein is a critical renal defense
factor protecting against calcium oxalate crystal formation. Kidney
Int. 66:1159–1166. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kelly DJ, Wilkinson-Berka JL, Ricardo SD,
Cox AJ and Gilbert RE: Progression of tubulointerstitial injury by
osteopontin-induced macrophage recruitment in advanced diabetic
nephropathy of transgenic (mRen-2)27 rats. Nephrol Dial Transplant.
17:985–991. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Vezzoli G, Soldati L and Gambaro G: Update
on primary hypercalciuria from a genetic perspective. J Urol.
179:1676–1682. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Shiraga H, Min W, VanDusen WJ, Clayman MD,
Miner D, Terrell CH, et al: Inhibition of calcium oxalate crystal
growth in vitro by uropontin: Another member of the aspartic
acid-rich protein superfamily. Proc Natl Acad Sci USA. 89:426–430.
1992. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Mo L, Liaw L, Evan AP, Sommer AJ, Lieske
JC and Wu XR: Renal calcinosis and stone formation in mice lacking
osteopontin, Tamm-Horsfall protein, or both. Am J Physiol Renal
Physiol. 293:F1935–F1943. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Lieske JC, Hammes MS, Hoyer JR and Toback
FG: Renal cell osteopontin production is stimulated by calcium
oxalate monohydrate crystals. Kidney Int. 51:679–686. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Khan SR, Glenton PA and Byer KJ: Modeling
of hyperoxaluric calcium oxalate nephrolithiasis: Experimental
induction of hyperoxaluria by hydroxy-L-proline. Kidney Int.
70:914–923. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Batinić D, Milosević D, Blau N, Konjevoda
P, Stambuk N, Barbarić V, et al: Value of the urinary stone
promoters/inhibitors ratios in the estimation of the risk of
urolithiasis. J Chem Inf Comput Sci. 40:607–610. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Gao B, Yasui T, Okada A, Tozawa K, Hayashi
Y and Kohri K: A polymorphism of the osteopontin gene is related to
urinary calcium stones. J Urol. 174:1472–1476. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Liu CC, Huang SP, Tsai LY, Wu WJ, Juo SH,
Chou YH, Huang CH and Wu MT: The impact of osteopontin promoter
polymorphisms on the risk of calcium urolithiasis. Clin Chem Acta.
411:739–743. 2010. View Article : Google Scholar
|
|
34
|
Gao B, Yasui T, Itoh Y, Li Z, Okada A,
Tozawa K, Hayashi Y and Kohri K: Association of osteopontin gene
haplotypes with nephrolithiasis. Kidney Int. 72:592–598. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Gögebakan B, Igci YZ, Arslan A, Igci M,
Erturhan S, Oztuzcu S, Sen H, Demiryürek S, Arikoglu H, Cengiz B,
et al: Association between the T-593A and C6982T polymorphisms of
the osteopontin gene and risk of developing nephrolithiasis. Arch
Med Res. 41:442–448. 2010. View Article : Google Scholar : PubMed/NCBI
|
